This 88-hour on-demand conference includes 64 sessions highlighting best practices and the latest science, research, and innovations in addiction medicine from leading experts in the field.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses advanced alcohol withdrawal management through case-based learning, covering validated assessment tools and treatment strategies for complex presentations.

This 60-minute on-demand session from the ASAM 57th Annual Conference addresses gas station accessible substances including tianeptine, phenibut, and alkyl nitrites, covering toxidromes, complications, and harm reduction strategies.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses direct-to-inject extended-release buprenorphine implementation, covering evidence, diverse healthcare settings, and practice-specific planning strategies.

This 75-minute on-demand session from the ASAM 57th Annual Conference addresses alpha-2 agonist withdrawal management in emergency and ICU settings, focusing on medetomidine toxicology and emerging treatment strategies.

This 60-minute on-demand session from the ASAM 57th Annual Conference addresses implementing hospital and emergency department SUD care, translating ASAM guidance into practical interprofessional implementation strategies.

In the Season 2 premiere of ASAM Practice Pearls, Drs. Stephen Taylor and Jeanmarie Perrone follow up on Season 1’s episode, Emerging Illicit Substances: What Clinicians Need to Know. Together, they discuss how medetomidine has continued to spread to different regions and what has changed over the past year. They explore strategies for managing medetomidine withdrawal, keeping patients safe, and preparing for this growing public health threat.

This 75-hour on-demand conference includes 64 sessions highlighting best practices and the latest science, research, and innovations in addiction medicine from leading experts in the field.

This 45-minute on-demand session from the ASAM 56th Annual Conference addresses the latest practices in buprenorphine initiation for adolescents in acute care, offering participants the chance to shape emerging guidance and empowering them to implement treatment protocols for OUD in their own institutions.

This 75-minute on-demand session from the ASAM 56th Annual Conference addresses the eligibility and benefits of 7-day extended release buprenorphine, insights from the CTN-0097 trial on extended release naltrexone, and approaches to collaborative care for opioid use disorder in primary care.